title: Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis.
abstract: Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide were studied in healthy controls and patients with active pulmonary tuberculosis. A case-control study of 29 controls and 30 cases attending at the Health Center, July, 2004 to December, 2005 was conducted. The body mass index was significantly reduced in cases compared to controls (p < 0.001). The intestinal paracellular transport of lactulose was significantly (p = 0.019) reduced in cases compared to controls. The transcellular transport of mannitol and the lactulose:mannitol ratio were not significantly (p = 0.0698) reduced in cases compared to controls. Low serum concentrations of rifampin, isoniazid and pyrazinamide were observed in 81% (48/59), 92% (54/59) and 28% (12/59), respectively, in all individuals. The results demonstrated a marked decrease on intestinal paracellular transport in patients with active pulmonary tuberculosis and reduced serum concentrations of rifampin and isoniazid in both groups.
authors.affiliation: Clinical Research Unit & Institute of Biomedicine, Center for Global Health, Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceará, Fortaleza. mfacanha@yahoo.com
authors.forename: Mônica C
authors.initials: MC
authors.lastname: Façanha
authors.forename: Argina M B
authors.initials: AM
authors.lastname: Gondim
authors.forename: Valéria G F
authors.initials: VG
authors.lastname: Pinheiro
authors.forename: Elizabeth C
authors.initials: EC
authors.lastname: Barroso
authors.forename: Charles A
authors.initials: CA
authors.lastname: Peloquin
authors.forename: Richard L
authors.initials: RL
authors.lastname: Guerrant
authors.forename: Aldo A M
authors.initials: AA
authors.lastname: Lima
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000502:physiology*; D007538:Isoniazid / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D008297:Male; D011718:Pyrazinamide / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D012293:Rifampin / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin